Meta-analysis

Method characteristics (e.g. study perspective, discount rates, costing methods, etc.) Health-care system characteristics (e.g. absolute and relative costs, practice variations, and technology availability) Population characteristics (e.g. disease incidence/prevalence. health-status preferences)
 * **Comparison through health economics evaluation**:

tree modeling || CYP2C9 VKORC1 || * Warfarin therapy is about to be initiated at least 3 months || A literature search (only English) from MEDLINE for the period January 1950 - July 2008 || ICER: event averted saved || Genotype -guided dosing for warfarin therapy is not cost- effective. ||
 * **Literature** || **Model** || **Enzyme** || **Population** || **Inputs** || **Main results** || **Conclusion** ||
 * [[file:YouEtal2009.pdf]] || Decision
 * At least 18 years old
 * Therapy prescibed for
 * USD347,059/QALY
 * USD170,192/adverse
 * USD1,106,250/life

to derive data** || **Population involved** || **Definition of each category** || dosing algorithm, and its impact on INR based effecacy || 1) Standard dosing followed the 10-mg warfarin nomogram of Kovacs et al 2) INRs were routinely measured on days 0, 3, 5, 8, 21, 60, and 90 || 1) Women who were pregnant, lactating, or of child-bearing potential; taking rifampin within 3 weeks; or patients with comorbidities precluding standard dosing were excluded 2) 94% are whites || 1) Out of range INR: < 1.8 or >3.2 2) Primary end point: the number of out-of-range INR values for each individual patient was divided by the total number of INRs for that patient to give an individual percent out-of-range value. ||
 * **Study** || **Purpose** || **Methods
 * [[file:(ref24)AndersonEtal2007.pdf]] || pharmacogenetic-guided
 * [[file:(ref38)ReynoldsEtal2004.pdf]] ||  ||   ||   ||   ||
 * [[file:(ref40)FangEtal2007.pdf]] ||  ||   ||   ||   ||
 * [[file:(ref43)ThomsonEtal2000.pdf]] ||  ||   ||   ||   ||